BMO Capital analyst Matthew Luchini reiterated a Buy rating on NGM Biopharmaceuticals (NASDAQ:NGM) Inc on Friday, setting a price target of $35, which is approximately 63.25% above the present share price of $21.44.
Luchini expects NGM Biopharmaceuticals Inc to post earnings per share (EPS) of -$0.48 for the fourth quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in NGM Biopharmaceuticals, with an average price target of $36.
The analysts price targets range from a high of $42 to a low of $32.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $16.77 million and a net profit of -$36.62 million. The company's market cap is $1.66 billion.
According to TipRanks.com, BMO Capital analyst Matthew Luchini is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 5.8% and a 44.88% success rate.
NGM Biopharmaceuticals, Inc. engages in the discovery and development of therapeutics for major diseases with an initial focus on cardio-metabolic and liver diseases. Its portfolio if composed of product candidates which focuses on non-alcoholic steatohepatitis, type 2 diabetes, obesity, oncology and age-related macular degeneration. The company was founded by Jin-Long Chen in 2008 and is headquartered in South San Francisco, CA.